Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Biological therapy, selective JAK-1 inhibitor, already registered for other diseases.
Main Inclusion Criteria: Patients older than 12 years, regardless of prior treatment, currently experiencing extensive (active) disease.
Status: Enrolling patients soon
Start of patient enrollment: August 2024.
Planned completion of new patient enrollment: November 2024.